Amgen Inc.
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell counā¦ read more
Healthcare
Drug ManufacturersāGeneral
43 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$391.27
Price-0.48%
-$1.90
1Y
Price
Market Cap
$211.172b
Large
Price/Earnings 3y Avg5y Avg
17.5x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+34.2%
EBITDA Margin+23.6%
Net Profit Margin+34.7%
Free Cash Flow Margin+34.2%
EBITDA Margin+23.6%
Net Profit Margin+34.7%
Free Cash Flow MarginRevenue
$38.125b
+3.8%
1y CAGR+10.8%
3y CAGR+9.8%
5y CAGREarnings
$8.743b
+13.4%
1y CAGR+20.9%
3y CAGR+16.3%
5y CAGREPS
$16.09
+13.1%
1y CAGR+20.6%
3y CAGR+16.2%
5y CAGRBook Value
$11.688b
$95.639b
Assets$83.951b
Liabilities$57.304b
DebtDebt to Assets
59.9%
3.5x
Debt to EBITDAFree Cash Flow
$10.175b
+25.6%
1y CAGR+14.9%
3y CAGR+7.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company